The Veteran's urticaria is rated at 30 percent effective from August 13, 2018. The condition requires the use of corticosteroids as second line treatment for control.
The deciding factor: The evidence shows that the Veteran requires the use of corticosteroids as a second line treatment for his urticaria.
- Claimed conditions
- urticaria
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating assigned
- 30%
- Decision date
- October 4, 2019
- Citation
- 19176903
What this means for you
A grant means the Board agreed the veteran was entitled to the benefit. Decisions like this show the kind of evidence and arguments that tend to succeed for claims like it.
What you can do next
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Denied
The Board denied the Veteran's claim for an initial compensable rating for urticaria, as there was no evidence that the condition required antihistamines or other first-line treatment for control during the review period.
- Denied
The Board denied TDIU and DEA prior to June 26, 2022 but granted SMC effective April 21, 2023.
- Remanded (sent back)
The Board remands the claim for service connection for a body rash to obtain an adequate medical opinion regarding whether the Veteran's current skin disability pre-existed his entrance to active service and, if not, whether it is related to his active service.
- Dismissed
The Board dismissed the claim for restoration of a 10 percent rating for urticaria, beginning November 1, 1975 due to clear and unmistakable error (CUE) because the August 1975 decision was subsumed by the April 1976 Board decision.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.